<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772940</url>
  </required_header>
  <id_info>
    <org_study_id>Lubumbashi trial</org_study_id>
    <nct_id>NCT01772940</nct_id>
  </id_info>
  <brief_title>Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting</brief_title>
  <official_title>Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In resource-limited setting, concerns remain regarding the emergence of virologic failure and
      high-level drug resistance mutations (DRM) during WHO recommended first-line antiretroviral
      therapy (ART) with non-nucleoside reverse transcriptase inhibitors (NNRTI) based regimens for
      Human immunodeficiency virus 1 (HIV1) infected patients. The study hypothesis is that a
      boosted-protease inhibitor regimen has a better outcome than a NNRTI-based regimen with a low
      genetic barrier to resistance.

      The study is a randomized, multicenter, factorial trial (conducted in Congo), in treatment-
      naïve adults receiving for 96 weeks ritonavir- boosted lopinavir(LPV/r) or nevirapine (NVP)
      each in combination with tenofovir (TDF) /emtricitabine (FTC) or zidovudine (ZDV)/lamivudine
      (3TC). The primary end point is the incidence of therapeutic (clinical and/or
      virologic)failure by study week 24.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of therapeutic failure</measure>
    <time_frame>At week 48 with follow-up until week 96</time_frame>
    <description>The primary end point is the proportion of patients with therapeutic failure defined as:
the occurence or relapse by week 24 of a World Health Organization (WHO) stage 4 or 3 event, or
death by week 24, or
discontinuation of study drugs due to toxicity at any time, or
virological failure defined as HIV-1 RNA &gt; 1000 copies/ml by week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA viral load less than 50 copies/ml</measure>
    <time_frame>Through week 96</time_frame>
    <description>The percentage of patients with HIV-1 RNA &lt; 50 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic response</measure>
    <time_frame>Through week 96</time_frame>
    <description>Cluster of differentiation 4 (CD4) cell count change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 resistance mutations</measure>
    <time_frame>At baseline and at the time of virologic failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Through week 96</time_frame>
    <description>Incidence of adverse events and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory parameters</measure>
    <time_frame>Through week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>nevirapine and tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lopinavir/r and tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevirapine and zidovudine/lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/r and zidovudine/lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine</intervention_name>
    <description>Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks</description>
    <arm_group_label>nevirapine and tenofovir/emtricitabine</arm_group_label>
    <arm_group_label>Nevirapine and zidovudine/lamivudine</arm_group_label>
    <other_name>Viramune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir-boosted Lopinavir</intervention_name>
    <description>ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks</description>
    <arm_group_label>lopinavir/r and tenofovir/emtricitabine</arm_group_label>
    <arm_group_label>Lopinavir/r and zidovudine/lamivudine</arm_group_label>
    <other_name>Aluvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/emtricitabine</intervention_name>
    <description>tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks</description>
    <arm_group_label>nevirapine and tenofovir/emtricitabine</arm_group_label>
    <arm_group_label>lopinavir/r and tenofovir/emtricitabine</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine/lamivudine</intervention_name>
    <description>zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks</description>
    <arm_group_label>Nevirapine and zidovudine/lamivudine</arm_group_label>
    <arm_group_label>Lopinavir/r and zidovudine/lamivudine</arm_group_label>
    <other_name>Zidolam,combivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antiretroviral-therapy naïve HIV-1 infected Adults

          -  WHO clinical stage 3 and CD4 &lt;350/mm3 or

          -  WHO clinical stage 4 or

          -  CD4 cell count &lt; 200/mm3

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Hemoglobin &lt; 8.5 g/dL (female) or 9.0 g/dL (male)

          -  Estimated Glomerular Filtration Rate &lt; 50 ml/ minute (Cockcroft-Gault equation)

          -  Hepatic transaminases (AST and ALT)&gt; 3 x upper limit of normal

          -  Active tuberculosis

          -  Pregnancy

          -  Females who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Clumeck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Saint Pierre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires de Lubumbashi</name>
      <address>
        <city>Lubumbashi</city>
        <state>Katanga</state>
        <country>Congo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Clumeck Nathan</investigator_full_name>
    <investigator_title>Chief infectious diseases , Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>First-line therapy</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Non-Nucleoside Reverse transcriptase Inhibitor</keyword>
  <keyword>Resource-limited setting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

